Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.
|Articles|December 1, 2002
Supplements and Featured Publications
- Patient-Reported Outcomes and Managed Care Decisions: Quality of Life and Related Components
- Volume 8
- Issue 18 Suppl
An Introduction to Quality-of-Life Assessment in Oncology: The Value of Measuring Patient-Reported Outcomes
Advertisement
Articles in this issue
almost 24 years ago
Participating Facultyalmost 24 years ago
Quality of Life and Symptom Measures in Oncology: An Overviewalmost 24 years ago
Quality-of-Life Measurements: A Soft Outcome - Or is it?almost 24 years ago
Continuing Medical Education QuizAdvertisement
Related to this article
Phase 3 trials found oveporexton improved wakefulness, sleepiness, and cataplexy in narcolepsy type 1, with insomnia and urinary frequency common.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.
Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.
Advertisement
Advertisement
Trending on AJMC
1
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
2
Drug Price Drives Value of MASH Therapies More Than Efficacy
3
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
4
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
5